Physician profile
Alexander Trezza
NPI 1437722873
$3,354.06
in general payments reported to CMS, 2019-2025
14 companies · $806 in 2025
The $806 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $153 · 2022: $1,681 · 2023: $304 · 2024: $410 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,141.43 | 2022-2025 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $547.57 | 2022-2025 | Infuse, Miebo, Xiidra |
| Alcon Vision LLC | $398.79 | 2022-2025 | Precision 1, Precision7, Total30 |
| Glaukos Corporation | $332.35 | 2025 | |
| Sight Sciences, INC. | $278.14 | 2022 | |
| Allergan, INC. | $245.97 | 2021-2022 | |
| Abbvie INC. | $120.29 | 2022 | |
| Sun Pharmaceutical Industries INC. | $87.39 | 2025 | |
| Oyster Point Pharma, INC. | $78.82 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $38.95 | 2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $33.79 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $18.76 | 2023 | Acuvue |
| Dompe US, INC. | $16.93 | 2024 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Trezza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.